Seres Therapeutics, Inc. (MCRB) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, thank you for standing by. My name is Desiree and I will be your conference operator today. At this time, I would like to welcome everyone to the Series Therapeutics First Quarter 2025 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, again, press the star one. I would now like to turn the conference over to Dr. Carlo Tanvi of Investor Relations. You may begin. Thank you and good morning. Our press release with the company's first quarter 2025 financial results and business updates became available at 7 a.m. Eastern time this morning and can be found on the investors and news section of the company's website. The company has also posted an updated corporate presentation to the website. I'd like to remind you that we'll be making forward-looking statements, including statements about the timing and results of our clinical studies and data readouts, future product candidates, clinical development plans and commercial opportunities, communications with, feedback from, or submissions to the FDA, upcoming presentations, future payments related to the valve sale, operating plans and our future cash runway, our ability to secure partnerships and or generate or obtain additional capital or financing, are planned strategic focus, anticipated timing of any of the foregoing or other statements which are not historical facts. Actual results may differ materially. Additionally, these statements are subject to certain risks and uncertainties, which are discussed under the risk...